Omnicell Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Omnicell (OMCL) Tops Q2 EPS by 14c, Revenues Beat; Offers 3Q EPS Outlook Below Consensus, 3Q Revenue Mid-Point Guidance Below Consensus
July 28, 2020 4:04 PM EDTOmnicell (NASDAQ: OMCL) reported Q2 EPS of $0.37, $0.14 better than the analyst estimate of $0.23. Revenue for the quarter came in at $199.6 million versus the consensus estimate of $182.42 million.
GAAP revenues of $199.6 million and net loss per diluted share of $0.10Non-GAAP revenues $199.6 million and net income per diluted share of $0.37Omnicells Response to Coronavirus (COVID-19)
Keeping in mind our role in the healthcare industry, we are continuing to closely monitor the COVID-19 pandemic. Our top priorities remain protecting the health and well-being of our customers, their patients, and our... More
